The objective of this study was to evaluate the effect of tumour necrosis factoralpha inhibitors (TNF-αI) on Alzheimer's disease-associated pathology.
The presence of A® deposits in the brain can lead to the activation of an immune response and the recruitment of glial cells. In response to toxic A® deposits, microglia undergo morphological and functional changes to neutralize them. 3 As glial cells are unable to remove the debris, their function becomes altered in a way that they actively contribute to inflammation. 4 Recent identification of genes associated with susceptibility to AD provided basis for establishing the first nondescriptive link between inflammatory processes and development of AD pathology. 5 Mutations in genes coding for triggering receptor expressed on myeloid cells 2 and myeloid cell surface antigen CD33 lead to a significantly increased risk of AD through impaired induction of inflammatory processes. 6, 7 Furthermore, studies on transgenic mice demonstrated that experimental induction of neuroinflammation initiated by administration of lipopolysaccharide leads to an increase in amyloid beta deposition. 8, 9 It has been demonstrated that tumour necrosis factor-alpha (TNF-α) can potentiate the astroglial response, driving the neuroinflammatory process. 10 Tumour necrosis factor-alpha along with interleukin-1 ® and interferon-γ can induce the cleavage of the amyloid precursor protein by gamma-secretase via activation of the mitogen-activated protein kinase pathway. 11 Tumour necrosis factorThis article was submitted in partial fulfilment of the requirements for a degree in neuroscience. This research was supported by University College London and Middlesex University.
| Inclusion/exclusion criteria
Studies were included if they met the following criteria: (1) published in a peer-reviewed journal without any language restrictions, (2) report original work, (3) conducted on animal subjects or human participants, (4) the intervention had to include an administration of a TNF-αI or a genetic intervention leading to ablation of the TNF receptor (TNFR).
(5) animal studies had to include transgenic or nontransgenic models of AD, and (6) human participants had to be diagnosed with AD. Conference proceedings, case studies, research protocols, and unpublished dissertations or theses were excluded. In addition, studies on cell cultures were excluded.
| Screening and data extraction
Studies were blindly and independently screened by 2 raters (J. E. and G. R.). Initially, titles and abstracts were screened and then full-text articles were retrieved for all potentially relevant studies. Discrepancies were resolved through discussion with an independent reviewer (R. G.). Two raters (J. E. and G. R.) blindly and independently extracted data on study characteristics, methodology of the study, and outcomes with respect to neuropsychiatric and neurohistopathological findings (as outlined in the Introduction). Again, any discrepancies were resolved through discussion with an independent reviewer (R. G.).
| Quality assessment of methodology
The methodological quality of studies was assessed to identify potential biases, confounding factors, and any errors that could affect the interpretation of the results. There is no agreed instrument for assessing methodology and risk of bias in animal studies. 19 Consequently, a quality assessment tool was developed for the purposes of this review based on criteria proposed by Krauth et al. Some of the criteria were unique to animal studies and allowed for the measurement of bias, reporting, and methodological issues. The Effective Public Health Practice Project Quality Assessment Tool 20 was used for human studies as it can be applied to all study designs. The quality
Key points
• The presence of toxic amyloid-beta deposits in the brain activates an inflammatory response, which further increases the production of the peptide. Increasing evidence suggests that the inflammatory processes play a central role in the pathogenesis of the disease.
Downregulating this process may be a potential treatment strategy.
• Results from animal studies showed a significant benefit associated with TNF-alpha inhibitors administration.
The number of human studies is too small to draw a conclusion, and further research in this area is necessary to establish the potential role of TNF-alpha inhibitors in ameliorating Alzheimer's disease pathology.
of studies was evaluated in the following categories: selection bias, study design, confounder, blinding, data collection methods, withdrawals and drop-outs, intervention integrity, and statistical analysis (see Appendix E found in the Supporting Information). The methodological quality of included studies was assessed by 2 blind, independent raters (J. E. and G. R.), with any discrepancies in ratings being resolved through discussion with an independent reviewer (R. G.).
| RESULTS

| Identification and characteristics of included studies
As shown in Figure 1 , 1038 potentially relevant studies were initially identified, from which 477 duplicates were removed, yielding a total of 561 potentially relevant studies. After initial screening of titles and abstracts, 526 studies were excluded. This resulted in the extraction of 35 full-text articles, 16 of which met the inclusion criteria.
| Study characteristics
Animal studies
Thirteen animal studies assessing the potential use of TNF-αI in the treatment of AD were identified (see Appendix A for detailed characteristics found in the Supporting Information). [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] The studies were very heterogeneous. Transgenic mice were subjects in 9 out of 13 studies. 21, 23, 24, [26] [27] [28] [29] 32, 33 Three studies used nontransgenic mice 22, 25, 31 and one was conducted on rats as well as transgenic mice. 33 The most common transgenic model of AD was 3xTg-AD type and was used in 4 studies. 23, 26, 29, 33 Aβ injections were used in 5 studies to induce similar changes to those seen in AD. 22, 25, 27, 28, 31 The number of animals was unreported in the majority of studies. Only 3 of them stated this number, which ranged from 9 to 22. 30, 32, 33 Consequently, it was not possible to calculate effect sizes. The most frequently used type of TNF-αI was 3,6′-dithiothalidomide, administered in 3 studies. 23, 31, 33 The methods of drug delivery included intraperitoneal, intracerebroventricular, subcutaneous injections, and stereotactic infusion. Peripheral administration via an intraperitoneal injection was the most common intervention, used in 7 studies. 23, 24, 26, 28, [31] [32] [33] The length of treatment ranged from 1 to 90 days. One paper did not report the duration of intervention. 29 
Human studies
Three studies on humans were identified (see Appendix B for detailed characteristics and Appendix C for inclusion/exclusion criteria found in the Supporting Information), which were heterogeneous in a number of areas. The types of study design included a randomized double-blind controlled trial, 34 nested case-control study, 35 and a prospective, singlecentre, open-label pilot study. 36 The number of participants ranged from 15 to 325. With respect to diagnosis, standard clinical criteria were used FIGURE 1 PRISMA flow chart [Colour figure can be viewed at wileyonlinelibrary.com] to diagnose AD in 2 studies 34, 36 and both RA and AD in one study. 35 Where reported, the age of participants ranged from 18 to 94 years, with the mean age ranging from 72. 4 
| Quality assessment
Animal studies
Ratings of the methodological quality of included animal studies are provided in Appendix D (found in the Supporting Information). Only 2 studies reported that treatment was allocated randomly. 22, 32 These studies also explicitly stated that the investigator involved in the experiment was blinded to the intervention. 22, 32 Blinding was only partially described in 3 studies. 24, 25, 31 None of the studies provided information on how the number of study animals was calculated.
The requirement for compliance with the Animal Welfare Act was met by all studies. Four studies declared no financial conflict of interest. 21, 22, 30, 32 The statistical methods used to analyse the results obtained were partially adequate 21, 25, 27, 29, 31, 32 or fully explained [22] [23] [24] 26, 28, 33 in all studies, except one. 30 The presence of any comorbidities in test animals was not reported in any of the studies. All of the studies provided partial information on the characteristics of the animal used, such as species, strain, genetic background, supplier, sex, and weight. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] None of the studies, however, reported enough detail to fully meet this criterion. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] No mention was made in any of the studies as to whether the dose-response pattern was suitable to address the hypothesis. All of the included studies failed to report if any animals had been withdrawn from the experiment before its completion. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] The time window for assessing the outcome of the experiments was rated as adequate in 12 out of 13 studies.
21-33
Human studies
Ratings of the quality of human studies are listed in Appendix E (found in the Supporting Information). The participants in the study by Butchart et al were likely to be representative of the target population.
There was a partial risk of selection bias in the study by Chou et al and Tobinick et al. Two out of 3 studies were randomized, and the study design was rated as adequate. 34, 36 The study by Chou et al was a retrospective case control analysis. The confounding factors were well controlled in one study. 34 It is unclear whether participants of the 2 remaining studies were exposed to any factors that may have affected the results. 35, 36 Blinding was adequate in only one study 34 hence, the intervention integrity was rated as inadequate.
Results of included studies
The findings in each subcategory are discussed below (see Appendix F for a summary of the key outcomes found in the Supporting Information).
Cognition and behaviour
In all studies that assessed changes in cognition and behaviour, the effect of TNF-αI was beneficial. Cavanagh et al showed that an increase in hippocampus-dependent synaptic function, an early pathological sign of AD, can be reversed by an administration of XPro1595.
Aβ-associated cognitive deficits in mice were also diminished by a subcutaneous injection of the TNF receptor 2 fused to a fragment crystallizable domain used clinically for the treatment of RA. 22 The animals showed a dose-related response in alternation percentage in the Ymaze, with a complete reversal of cognitive deficits at 30 mg/kg. 22 Changes in exploration of the radial arm on administration of 3,6′-dithiothalidomide, but not thalidomide, in 3xTg mice were observed in one experiment. Another study revealed that treatment with a COX-2 inhibitor and AbTNF-alpha in 57BI/6 and TNFR1 knock-out mice prevented cognitive decline and led to an improvement in spatial learning deficits. 
| Reduction in brain tissue mass
None of the studies investigated the effect of TNF-αI on brain tissue mass.
| Presence of plaques and tangles
Although the majority of included animal studies reported a reduction in the quantity of neuropathological features, the results were not fully consistent. Gabbita et al 23 showed no differences in the number of 
| DISCUSSION
The main findings of this systematic review will be summarized below and compared with the findings of previous reviews. The clinical and research implications and strengths and limitations of the current review will also be discussed.
| Previous findings
Evidence from animal studies presented in this review supports the mechanism underlying the use of TNF-αI in ameliorating AD pathol- 
| Research implications
The role of the TNF signalling pathway has been a subject of many The effectiveness of pentoxifylline on slowing down the progress of mental deterioration in patients with a diagnosis of multi-infarct dementia has also been investigated. 38 A significant improvement on the Gottfries-Bråne-Steen scale was seen. However, the study reported no decline in MMSE score over a 9-month period, which might imply that patients diagnosed with AD did not participate in the trial or that the treatment period was too short. Investigating the effect of pentoxifylline on patients with a diagnosis of AD would be desirable.
Butchart et al used 6 neuropsychometric tests to assess the effect of subcutaneous etanercept on secondary clinical outcomes.
After correcting for multiple comparisons, no statistically significant differences in scores on the neuropsychometric tests were found. 34 Based on these results, it may be suggested that a TNF-αI with different pharmacokinetic properties should be tested in a clinical trial.
Evidence from a study of the effect of thalidomide, etanercept, and infliximab on rat models of dementia showed that the thalidomidetreated group performed best in the Morris water maze test. 39 This finding suggests that future research should investigate the effect of thalidomide on AD pathology.
Currently, only limited evidence of the effect of TNF-αI on synaptic function is available and more research in this area is required. None of the studies measured reduction in brain tissue mass. Given that this is a good indication of disease severity, future research should take this into consideration.
| Clinical implications
It has been shown that an increase in synaptic function of glutamatergic neurons occurs before the development of AD pathology, subsequently leading to deleterious effects on cognition. 40 The administration of an TNF-αI in the study by Cavanagh et al diminished the observed abnormalities. For this reason, treatment with TNF-αI could prove beneficial for patients in the initial stages of the disease.
| Strengths and limitations
The main strengths of the review were that a broad range of studies were searched across 6 databases. Furthermore, extracting the infor- 
